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OBJECTIVES: Our study seeks to assess national variations in physician diagnosis of 
Attention Deﬁcit Hyperactivity Disorder (ADHD) and test a hypothesis that family 
practitioners are more likely to diagnose and prescribe medications for ADHD than 
specialists. Further, the study seeks to examine trends and patterns in the use of stimu-
lant medications in children and adolescents with ADHD. METHODS: We used data 
from National Ambulatory Medicare Care Survey (NAMCS), an on-going annual 
survey of a representative sample of US ofﬁce-based physician practices. The frequency 
and rate of ADHD-related visits were analyzed using a weighted sample of youths 
aged 18 years and younger and trends were tracked for diagnostic prevalence and 
psychotropic medication use for the years 2003–2006. Utilization of psychotropic 
medications was focused on stimulant drug use and second line ADHD medications. 
RESULTS: A total of 5,319,764 visits having ADHD as primary diagnosis were identi-
ﬁed in 2006, representing an increase of about 11% from 2003. The primary diagnosis 
of ADHD was made increasingly by non specialist physicians (pediatricians, family 
practitioners, internists and others; from 43.3% in 2003 to 64.9 % in 2006) compared 
to specialists (child and general psychiatrists and neurologists) during the period 
covered. As pediatrician diagnosis of ADHD rose from to 32.5% in 2003 to 50% in 
2006, diagnosis by child psychiatrists declined signiﬁcantly from 37.3% to 18.9% (P 
< 0.05) during the same period. The prescribing of long-acting stimulants increased 
from 42.8 % in 2003 to 47.1 % in 2006, and an opposite trend was observed for the 
short-acting agents during the same period (decreased by 8.5 %). CONCLUSIONS: 
Nonspecialist physicians are more likely to diagnose ADHD and prescribe psychotro-
pic medications than specialists, further underscoring the controversy surrounding 
ADHD treatment. Dramatic changes in the patterns of psychotropic medication use 
in outpatient medical practice may be a cause for concern.
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OBJECTIVES: This study assessed the clinical and functional outcomes following a 
switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia 
patients in Japan. METHODS: We used data from a large 1-year prospective, multi-
center, observational non-interventional study of individuals who were initiated on 
olanzapine for the treatment of schizophrenia in Japan. Current analysis focused on 
patients who were switched at study entry from risperidone to olanzapine (n = 258). 
Changes from baseline to endpoint on clinical and functional measures were assessed 
with validated measures. Repeated measures analysis was employed for longitudinal 
measures. RESULTS: At study entry, 45% were inpatients and 55% outpatient. 
Participants were in their early 40s’ with mean illness duration of 14 years. About 
half were male. Most were switched from risperidone to olanzapine due to poor 
medication efﬁcacy (67.8%) and fewer were switched due to medication intolerability 
(29.1%). Most patients (67.8%) completed the 1-year study. During the follow up 
period, patients experienced clinically meaningful and statistically signiﬁcant (p < 0.05) 
improvements in overall symptom levels, on positive, negative, depressive and cogni-
tive symptoms, on quality of life and on paid work rates. Most patients (59.2%) 
demonstrated treatment response to olanzapine and 43.4% experienced symptom 
remission. Mean weight gain was 2.19 kg, with one- third of patients experiencing 
clinically meaningful weight gain (at least 7% of baseline weight). Most patients 
(76.0%) maintained their initial BMI category. CONCLUSIONS: In this 1-year natu-
ralistic study of patients with schizophrenia in Japan, inpatients and outpatients who 
were switched from risperidone to olanzapine experienced clinically meaningful and 
statistically signiﬁcant improvements in their clinical and functional outcomes, which 
were accompanied by a clinically meaningful weight gain for one-third of the patients. 
Current ﬁndings highlight the favorable beneﬁt to risk proﬁle of switching to olan-
zapine therapy following treatment failure on risperidone among schizophrenia 
patients in Japan.
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OBJECTIVES: To assess whether a brief and simple assessment of patients’ early 
perceptions of medications’ beneﬁts can predict subsequent response or non-response 
to continued treatment with the same antipsychotic medication. METHODS: This 
post-hoc analysis used data from a cost-effectiveness study of antipsychotics in the 
treatment of schizophrenia (HGGD) in which the Rating of Medication Inﬂuences 
scale (ROMI) was assessed following 2 weeks of treatment. Patients rated ROMI items 
on a scale from 1 (no agreement) to 3 (strong agreement). Patients’ scores on the 
ROMI’s “Perceived Medication Beneﬁts,” a 4-item subscale identiﬁed in prior 
research, were used to predict subsequent response to continued treatment with the 
medication at Week 8. Response was deﬁned as at least 20% reduction on the Positive 
and Negative Syndrome Scale (PANSS) total score from baseline to Week 8. Logistic 
regression was used to assess whether the ROMI “Perceived Medication Beneﬁts” 
score was a strong predictor of subsequent response and identify the best cut-off score 
for the prediction model. Analysis was conducted on 439 patients who had PANSS 
and ROMI data at the 2-week and 8-week time points. RESULTS: A score of 2.75 
or higher on the Perceived Medication Beneﬁts subscale at Week 2 predicted subse-
quent response (per PANSS) at Week 8 with high speciﬁcity (72%) and negative 
predictive value (70%), moderate sensitivity (44%) and positive predictive value 
(47%) and with a 38% misclassiﬁcation rate. CONCLUSIONS: A brief assessment 
of patients’ early perceptions of medications’ beneﬁts (at Week 2) appears to be a 
good predictor of subsequent response/non-response to continued treatment with the 
same medication. Predictive values appear comparable to those reported in prior 
studies in which early response was assessed with a clinician-rated symptom scale, 
which requires special training and repeated assessments. Further research is needed 
to replicate the current ﬁndings.
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OBJECTIVES: To assess the long-term clinical, functional and safety-related outcomes 
following a switch from typical antipsychotics to olanzapine in the treatment of 
schizophrenia patients in Japan. METHODS: Using data from a large 1-year prospec-
tive, multi-center, observational non-interventional study of olanzapine for the treat-
ment of schizophrenia in Japan, patients who were switched from any oral typical 
antipsychotic to olanzapine were identiﬁed. Changes from baseline to endpoint in 
clinical and functional measures and in body weight were evaluated. Mixed model 
with repeated measures, controlled for baseline demographics, were applied. 
RESULTS: Of 262 patients who switched from typical antipsychotics to olanzapine, 
41% were outpatients and 59% inpatient. Most of these patients (71.0%) were 
switched due to poor medication efﬁcacy and 25.6% due to medication intolerability. 
Participants, on average, were chronically ill, in their late 40’s, with a 20-year history 
of schizophrenia. About half (51.9%) were male. Most patients (71.4%) completed 
the 1-year study. Clinically meaningful and statistically signiﬁcant (p < 0.01) improve-
ments from baseline to the ﬁnal study visit were observed in patients’ illness severity 
and quality of life, with improvements in overall symptom severity level and in posi-
tive, negative, depressive and cognitive symptoms. Most patients (58.3%) demon-
strated a treatment response to olanzapine and 47.4% achieved symptom remission. 
Mean weight gain from baseline to endpoint was 2.31 ± 4.72 kg, with 30.4% of 
patients experiencing clinically meaningful weight gain (at least 7% of baseline 
weight). Most (75.6%) patients maintained their initial BMI category at baseline. 
CONCLUSIONS: During the long-term naturalistic treatment of schizophrenia 
patients in Japan, the switching from typical antipsychotics to olanzapine appears to 
result in signiﬁcant improvements in patients’ clinical and functional outcomes, this 
is associated with clinically meaningful weight gain in one-third of patients. Findings 
highlight the potential beneﬁts and risks associated with switching to olanzapine fol-
lowing failure on typical antipsychotics.
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OBJECTIVES: Adjunctive treatments with atypical antipsychotics have demonstrated 
efﬁcacy in major depressive disorder (MDD) patients that respond insufﬁciently to 
conventional antidepressants. As most trial designs have limited duration, simulation 
allows for extrapolation, to inform on optimal treatment sequences over a longer 
period. We estimated the life-time health outcomes for augmentation therapies with 
atypical antipsychotics in MDD patients who fail to respond to conventional antide-
pressants. METHODS: A discrete event simulation model was built simulating MDD 
patients between major depressive episodes (MDEs) and remission periods over life-
time based on published data. During MDEs, patients were treated with adjunctive 
aripiprazole, quetiapine or olanzapine. Patients who did not respond at 6 weeks were 
switched to subsequent treatment lines. Comparative effectiveness between treatments 
was imputed using an indirect comparison combining 6-week published studies. 
Health related quality of life (QoL) data were obtained from published studies. 
Uncertainty of results was assessed by probabilistic sensitivity analyses (PSA). 
RESULTS: Over life-time, compared to adjunctive quetiapine and olanzapine, patients 
starting on adjunctive aripiprazole spent less time in MDEs compared to quetiapine 
(0.11 years) and olanzapine (0.17 years) and had an improvement of 0.06 and 0.04 
quality adjusted life years respectively. PSA estimated an 88% and 80% probability 
that aripiprazole improved QoL compared to quetiapine and olanzapine respectively. 
CONCLUSIONS: This novel DES model is well suited to account for the highly 
heterogeneous patient population, the deteriorating disease course and the use of 
different sequential treatment alternatives that is speciﬁc to MDD. The results indicate 
